首页> 外文期刊>Biosensors & Bioelectronics: The International Journal for the Professional Involved with Research, Technology and Applications of Biosensers and Related Devices >The strategy of antibody-free biomarker analysis by in-situ synthesized molecularly imprinted polymers on movable valve paper-based device
【24h】

The strategy of antibody-free biomarker analysis by in-situ synthesized molecularly imprinted polymers on movable valve paper-based device

机译:通过原位的抗体生物标志物分析策略在可移动阀纸的装置上合成分子印迹聚合物

获取原文
获取原文并翻译 | 示例
           

摘要

In this work, we provided a novel strategy of antibody-free biomarker analysis by in-situ synthesized molecularly imprinted polymers (MIPs) on movable valve microfluidic paper-based electrochemical device (Bio-MIP-ePADs) for clinical detection of biomarkers. The newly movable valves on the device enable continuous and convenient delivery of fluid, which guarantee the performance for fabricating MIPs structure during long time electro-polymerization. Moreover, this strategy can directly detect antigens by taking advantage of molecular imprinting on paper-based device, which greatly decreases the cost during clinical testing, reduces the tedious washing procedure and does not need to consider the preservation of the antibody in enzyme linked immunosorbent assay (ELISA). This feature makes the chip suitable for the on-site family treatment or commercial products. To further validate the applicability of this proposed method for clinical diagnostic testing, carcinoembryonic antigen (CEA) was applied as prototyping model target for the clinical analysis. The proposed Bio-MIP-ePADs were cheap, easy to prepare, disposable and provided reliable analysis by comparing with ELISA. We hope the application of this technology will open up a new avenue to the point-of-care testing (POCT).
机译:在这项工作中,我们提供了通过原位合成的分子压印聚合物(MIPS)在可移动阀微流体纸电化学装置(Bio-MIP-EPAD)上的抗体生物标志物分析的新策略,用于临床检测生物标志物。该装置上的新可移动阀能够连续和方便的流体输送,这保证了在长时间电聚期间制造MIPS结构的性能。此外,该策略可以通过利用纸张的装置上的分子印迹直接检测抗原,这大大降低了临床测试期间的成本,降低了繁琐的洗涤过程,并且不需要考虑酶联的免疫吸附测定中的抗体的保存(ELISA)。该功能使芯片适用于现场家庭治疗或商业产品。为了进一步验证该提出的临床诊断测试方法的适用性,将癌胚抗原(CEA)应用于临床分析的原型模型靶标。通过与ELISA相比,拟议的生物覆膜膜板是便宜的,易于制备,一次性和提供可靠的分析。我们希望这项技术的应用将向护理点测试(POCT)开辟新的大道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号